May 12, 2015

Juventas Therapeutics Raises $13.5 Million for Clinical Trials

Juventas Therapeutics, a Cleveland-based clinical-stage company developing regenerative therapies for treatment of cardiovascular diseases, has secured $13.5 million in financing to support future clinical studies.
Green Cross Holdings and POSCO Capital led a $7.5 million Series B-2 equity investment, which included participation from other new and existing investors. Juventas also received $6 million in debt financing through Oxford Finance LLC, and the company has the opportunity to secure an additional $9 million if certain milestones are met.